**Table 1:**

|  |  |
| --- | --- |
| **Patient baseline characteristics (n=75)** | |
| **Age, years, median (IQR)** | 64,8 (59-73) |
| **Female/Male,** | 28/47 |
| **Days from symptoms onset to CCP, days, median (IQR)** | 17 (10-24,5) |
| **Initial CT level, median (IQR)** | 22,9 (17,5-26) |
| **Anti-CD20 pre exposure** (unknown n=2) | |
| Yes, n(%) | 50 (68) |
| No, n(%) | 22 (30) |
| **Pre exposure to monoclonal antibodies** | |
| Yes, n(%) | 7 (9) |
| No, n(%) | 68 (91) |
| **Vaccination (two doses)** | |
| Yes, n(%) | 68 (91) |
| No, n(%) | 7 (9) |
| **Initial anti-S antibodies > 260 BAU/mL** (unknown n=5) | |
| > 260 BAU/mL, n(%) | 8 (11) |
| < 260 BAU/mL, n(%) | 62 (89) |
| **Underlying diseases** | |
| Hematological disease, n(%) | 52 (69) |
| Transplant recipient, n(%) | 12 (16) |
| Autoimmune disease, n(%) | 9 (12) |
| **Positive RNAemia** (unknown n=57) | |
| Yes, n(%) | 13 (72) |
| No, n(%) | 5 (28) |
| **WHO score** (unknown n=3) | |
| 5, n(%) | 49 (68) |
| 6, n(%) | 23 (32) |
| **Others treatment for COVID 19** (unknown n=23) | |
| Dexamethasone, n(%) | 37 (71) |
| Tocilizumab, n(%) | 5 (10) |